John W. Ostrominski, MD, is a fellow in Cardiovascular Medicine and Obesity Medicine at Brigham and Women’s Hospital and Harvard Medical School.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
New FINEARTS-HF Findings Provide Clarity on Balancing Risk and Benefit in HF, CKD
March 31st 2025At the American College of Cardiology 2025 Annual Scientific Session, John W. Ostrominski, MD, of Brigham and Women’s Hospital, dives into the nuanced safety profile of finerenone for high-risk patients with heart failure.